Ligand Pharmaceuticals | LGND - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Agenus USD -271.11M 3.03M 2025-12
Amgen USD 8.66B 961M 2025-12
Anika Therapeutics USD 143.46M 3.34M 2025-12
Arrowhead Research USD 568.42M 102.37M 2025-12
Baxter International USD 6.13B 1.11B 2025-12
Bristol-Myers Squibb USD 18.55B 1.06B 2025-09
Eli Lilly USD 26.54B 2.74B 2025-12
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Enviri Corporation USD 255.06M 106.02M 2025-12
Gilead Sciences USD 22.62B 1.16B 2025-12
GlaxoSmithKline GBP 16.38B 229M 2025-12
Glaxosmithkline GBP 22.06B 360M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
Insmed USD 738.98M 206.6M 2025-12
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 617.97M 13.76M 2025-09
Karyopharm Therapeutics USD -269.26M 30.33M 2025-09
Ligand Pharmaceuticals USD 1.02B 67.04M 2025-12
MacroGenics USD 55.59M 11.41M 2025-12
Merck USD 51.85B 2.79B 2025-09
Pacira USD 693.11M 34.1M 2025-12
Pfizer USD 92.8B 4.11B 2025-09
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Veracyte USD 1.26B 36.61M 2025-09